Delivery Innovation as a Second Engine of Value Alongside its core therapeutic development efforts, SureNano Science is also eyeing differentiated drug-delivery technologies designed to improve patient accessibility and long-term adherence
Shih et al., 2019), triggering chronic inflammation and arterial damage that promote atherosclerotic lesions (Fatkhullina et al., 2018
Ether lipids promote susceptibility to ferroptosis, particularly when containing a polyunsaturated fatty acyl (PUFA) chain 51,52
What is a GLP-1 Injection
(2019) reported that urinary NGAL accurately predicted AKI development in 27 subjects, identifying NGAL as a strong early marker of AKI. Despite this, managing CKD in liver transplant recipients remains challenging, with limited options to prevent or mitigate the progression of kidney damage